Director, Microbial Genomic Services
JAX Genomic Medicine
- Azitra has been awarded a SBIR Grant to support development of a microbiome therapeutic for Netherton Syndrome, an orphan skin disease...NS is extremely rare, it is a severe and unmet need...
Dr. Adams comes from a rich background including industry, government, academic, and nonprofit settings. Throughout, he has focused on applying leading-edge genomic and bioinformatic approaches to a variety of research problems in biology.
As one of the founding scientists at TIGR, Dr. Adams contributed extensively to the first genome sequence of a free-living organism, Haemophilus influenzae, and other microbial genomes. A co-founder of Celera Genomics, he led the DNA sequencing and genome annotation groups. He directed the Drosophila, human, and mouse genome sequencing projects, and a large-scale re-sequencing program to identify novel SNPs in humans.
From 2003-2011, Dr. Adams was Associate Professor of Genetics at Case Western Reserve University where he developed a research program in the evolution and mechanisms of antibiotic resistance in the nosocomial pathogen Acinetobacter baumannii. He also served as Director of the Genomics Core facility.
From 2011-2016, Dr. Adams was the Scientific Director and Professor at the J. Craig Venter Institute. There he directed programs that characterized genomic changes in the evolution of antibiotic resistance in hospital-acquired infections.
Dr. Adams received a B.A. in Chemistry from Warren Wilson College in Swannanoa, NC and a Ph.D. in Biological Chemistry from the University of Michigan.
Executive Director, Venture Development
Dr. Analoui is executive director of venture development and the Technology Incubation Program (TIP) at the University of Connecticut. Previously, he was head of healthcare and life sciences at Livingston Securities, with investment focus in private and public companies in biotech, medtech and healthcare services. Prior to that, he was the senior director at Pfizer Global Research and Development. Analoui is actively involved in investment, management and scientific/business development of nanotechnology, drug discovery/development, diagnostic imaging and global strategies.
At Pfizer, he was the site head for global clinical technology in Groton and New London, focusing on emerging technologies for development and validation of biomarkers and diagnostics for drug development. Prior to joining Pfizer, Analoui was the director of Oral and Maxillofacial Imaging Research, associate professor of radiology at Indiana University, and associate professor of biomedical engineering and electrical & computer engineering at Purdue University. He was also president and CEO of Therametric Technology Inc. He received his Ph.D. from Purdue University, followed by a postdoctoral fellowship at IBM T. J. Watson Research Center in New York.
Analoui consults and lectures in the United States, Europe and Asia. He has also served on various scientific, regulatory and business advisory committees and boards, including the National Institutes of Health, the National Science Foundation, Pharmaceutical Researchers and Manufacturers of America, the National Aeronautics and Space Administration, and the Organisation for Economic Co-operation and Development. Analoui has authored over 130 publications. Analoui is currently an adjunct professor at Brown University, Northeastern University and the University of Connecticut. He is also a senior member of the Institute of Electrical and Electronics Engineers, SPIE—the International Society for Optical Engineering, and the Radiological Society of North America.
He was board chairman for VirtualScopics and currently serves on the boards of Cyclica, Biomedical Engineering Alliance and Consortium, and NanoBusiness Commercialization Association.
Managing Director, Office of Cooperative Research
Jon Soderstrom is currently the Managing Director of the Office of Cooperative Research at Yale University. The Office manages the intellectual assets created at Yale to achieve the maximum benefit for the public and provide a financial return to support the University’s research efforts. He is responsible for managing the intellectual property portfolio of Yale faculty members, including (1) defining and executing commercialization strategies including negotiation of licenses and corporate-sponsored research agreements, (2) initiating strategic corporate partnerships, and (3) development and marketing of business concepts for new spin-off companies to the venture investment community.
Since joining the Office in 1996, he has helped form more than 25 new ventures including Molecular Staging (acquired by Qiagen), Agilix, Achillion Pharmaceuticals (NASQ: ACHN), PhytoCeutica (acquired by Kadmon),Protometrix (acquired by Invitrogen), Iconic Therapeutics, Applied Spine Technologies, HistoRx(acquired by Genoptix), VaxInnate, Affomix, KolltanPharmaceuticals (acquired by Celldex), Arvinas and Artisan Bioscience. Collectively, these companies have raised over $500 million in professional venture capital.
In 2007, the Office created the Yale Entrepreneurial Institute to help undergraduate, graduate and professional school students at Yale to start scalable new ventures. Over 100 new ventures have been formed that have raised over $135 million in investment capital.
Prior to this position, Dr. Soderstrom was the Director of Program Development for Oak Ridge National Laboratory (ORNL) after serving for ten years as Director of Technology Licensing for Martin Marietta Energy Systems. In the Office of Technology Transfer, he directed a group of ten professionals responsible for negotiating licenses and Cooperative Research and Development Agreements (CRADAs).
Dr. Soderstrom was a founding board member and past president of the Association of Federal Technology Transfer Executives as well as a member of the Licensing Executive Society and Association of University Technology Managers where he was, in 2008, President and, from 2003 – 2005, Vice President for Public Policy as well as a member of the Executive Committee of the Board of Directors. He is frequently asked to lecture and teach seminars on various aspects of the technology commercialization process and economic development both within the United States and abroad. He has testified before Congress on technology transfer issues and served as an expert witness in patent infringement litigation.
In addition to his professional accomplishments, Dr. Soderstrom was honored as the 87th “Point of Light” by President George H. W. Bush in March, 1990 for volunteer work with low-income families in East Tennessee to build and rehabilitate housing and provide other essential services.
Dr. Soderstrom received his Ph.D. from Northwestern University in 1980 and his B.A. from Hope College in 1976.